| Literature DB >> 29071477 |
Kodai Kuriyama1, Yutaka Enomoto2,3, Ritsuro Suzuki4, Jyuri Watanuki1, Hiroki Hosoi1, Yusuke Yamashita1, Shogo Murata1, Toshiki Mushino1, Shinobu Tamura1, Nobuyoshi Hanaoka1, Martin Dyer5, Reiner Siebert6,7, Hiroshi Kiyonari8,9, Hideki Nakakuma1, Toshio Kitamura2, Takashi Sonoki10.
Abstract
MicroRNA142 (MIR142) is a target of chromosome translocations and mutations in human B-cell lymphomas. We analyzed an aggressive B-cell lymphoma carrying t(8;17)(q24;q22) and t(6;14)(p21;q32), and sought to explore the role(s) of MIR142 in lymphomagenesis. t(8;17)(q24;q22) involved MYC on 8q24 and pri-MIR142 on 17q22. MYC was activated by a promoter substitution by t(8;17)(q24;q22). t(8;17)(q24;q22) was an additional event after t(6;14) (p21;q32), which caused the over-expression of CCND3. Southern blot analyses revealed that the MIR142 locus was deleted from the affected allele, whereas Northern analyses showed over-expression of MIR142 in tumor cells. Although previous studies reported an over-expression of mutations in MIR142 in B-cell lymphomas, limited information is available on the functions of MIR142 in lymphomagenesis. Therefore, we generated bone marrow transplantation (BMT) and transgenic (Eμ/mir142) mice, which showed enforced expression in hematopoietic progenitor cells and B cells, respectively. BMT mice showed decreased numbers of all lineage-positive cells, particularly B cells, in peripheral blood. Eμ/mir142 mice showed decreased numbers of IgM-positive splenocytes, and exhibited altered B-cell phenotypic changes induced by lipopolysaccharide. Our results suggest that over-expression of MIR142 alters B-cell differentiation, implying multi-step lymphomagenesis together with MYC activation and CCND3 over-expression.Entities:
Keywords: B-lymphoma; CCND3; Chromosome translocation; MYC; MicroRNA142
Mesh:
Substances:
Year: 2017 PMID: 29071477 DOI: 10.1007/s12185-017-2360-8
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490